How the FDA Approves New Drugs

Why Drug Approval Matters

Every pill you swallow has passed through one of the world's most rigorous evaluation systems. The U.S. Food and Drug Administration (FDA) requires that every new prescription drugPrescription Drug

A medication that legally requires a healthcare provider's prescription before dispensing. Prescription-only status is assigned when a drug's risks require professional supervision — due to side effec

be proven both safe and effective before it can be sold in the United States. This process exists because history has repeatedly shown what happens when drugs reach patients without thorough vetting.

The most famous cautionary tale is thalidomide. In the late 1950s, this sedative was prescribed widely in Europe to treat morning sickness in pregnant women. It caused severe birth defects in thousands of children. The FDA's refusal to approve thalidomide — largely due to the persistence of one reviewer, Dr. Frances Kelsey — helped protect American families. That experience directly led to the 1962 Kefauver-Harris Amendment, which requires manufacturers to prove efficacyEfficacy

The maximum therapeutic effect a drug can produce, regardless of the dose given. A drug with higher efficacy can achieve a greater maximum response than one with lower efficacy, even if the latter is

, not just safety.

Understanding how the FDA works helps you appreciate why new drugs take so long to reach the market, why some promising therapies are denied approval, and how the system sometimes accelerates review when the medical need is urgent.

Step 1: Preclinical Research

Long before any human takes an experimental compound, researchers study it extensively in laboratory settings. Preclinical research typically involves:

• In vitro studies: Testing how the compound behaves in cell cultures. Does it kill cancer cells? Block a virus? Inhibit a specific enzyme?
• In vivo studies: Testing in animals (usually rodents and at least one non-rodent species) to observe toxicity, dosing ranges, and biological effects.
• Pharmacokinetic profiling: Understanding how the drug is absorbed, distributed, metabolized, and excreted (ADME).

This phase can take two to five years. Most compounds fail here — estimates suggest that only about 1 in 5,000 to 10,000 compounds that enter preclinical testing will ultimately reach patients.

At the end of preclinical work, a pharmaceutical company must decide: Is this compound safe enough and promising enough to test in humans?

Step 2: Investigational New Drug ApplicationNew Drug Application

The formal request submitted to the FDA by a pharmaceutical company to gain approval to market a new drug in the United States. An NDA contains comprehensive data on the drug's chemistry, manufacturin

(IND)

Before a company can begin testing a drug in humans, it must file an Investigational New Drug (IND) application with the FDA. This document includes:

• All preclinical data
• The proposed clinical trial protocols
• Detailed information about the drug's manufacturing and composition
• Safety data and risk assessments
• Qualifications of the investigators conducting the trials

The FDA has 30 days to review the IND. If the agency does not place a clinical hold on the application within that period, the company may proceed. The FDA can issue a clinical hold if it believes there is an unreasonable risk to human subjects.

Step 3: Clinical Trials — Phases I–III

Clinical trials are the cornerstone of the FDA's evidence-based approval process. They are divided into distinct phases, each with a specific purpose.

Phase I: Safety in Humans

Phase I trials typically involve 20 to 100 healthy volunteers (though for drugs targeting serious diseases like cancer, patients themselves may participate). The primary goals are:

• Determining the safest dose range
• Understanding how humans metabolize the drug
• Identifying major side effects

These trials are not designed to prove the drug works. They are designed to answer one central question: Can humans tolerate this compound without serious harm? Phase I trials last roughly one to two years, and about 70% of drugs successfully pass this stage.

Phase II: Efficacy and Dosing

Phase II trials enroll 100 to 500 patients who have the disease or condition the drug is intended to treat. Goals include:

• Gathering initial evidence that the drug actually works (efficacy signals)
• Further refining the optimal dose
• Identifying side effects in a patient population (who may react differently than healthy volunteers)

About one-third of drugs successfully move past Phase II. Many fail not because of safety, but because early efficacy signals don't hold up when tested in actual patients.

Phase III: Large-Scale Confirmation

Phase III trials are the definitive test. They enroll hundreds to thousands of patients at multiple research sites, often across multiple countries. These trials are almost always randomized and double-blind — some participants receive the experimental drug, others receive a placebo or the current standard of care, and neither the participants nor the investigators know who is receiving which.

Phase III trials answer:

• Does the drug work better than what already exists?
• What is the full safety profile at the therapeutic dose?
• Do benefits outweigh risks in a large, diverse population?

Phase III can take three to five years and costs hundreds of millions of dollars. About 25–30% of drugs fail at this stage.

Step 4: New Drug Application (NDA)

If Phase III results are positive, the company submits a New Drug Application (NDA) to the FDA. This is an enormous document — often hundreds of thousands of pages — containing:

• All preclinical and clinical trial data
• Proposed labeling (the package insert)
• Manufacturing and quality control information
• Details on how the drug is synthesized and tested

For biologics (including many modern cancer therapies and vaccines), a Biologics License Application (BLA) is filed instead, reviewed by a different FDA center (CBER or CDER, depending on the product).

Step 5: FDA Review

The FDA assigns a team of scientists — physicians, pharmacologists, chemists, biostatisticians, and others — to review every aspect of the NDA. The review typically takes six to twelve months for a standard review, though priority review (see below) can shorten this to six months.

During review, the FDA may:

• Convene an advisory committee (a panel of outside experts) to provide independent recommendations
• Conduct an inspection of the manufacturing facilities
• Request additional data or clarification from the company

At the end of the review, the FDA issues one of three decisions:

1. Approval: The drug may be marketed as proposed.
2. Complete Response Letter (CRL): The FDA has concerns that must be addressed before approval can be granted.
3. Refusal to File: The application is so deficient it will not be reviewed.

Step 6: Post-Market Surveillance

Approval is not the end of the safety story — it is the beginning of a new chapter. The FDA requires ongoing post-market surveillance because clinical trials, however large, cannot detect every rare adverse event.

Post-market activities include:

• Phase IV trials: Sometimes the FDA requires manufacturers to conduct additional studies after approval to confirm benefits or monitor long-term safety.
• MedWatch: Healthcare providers and patients can voluntarily report adverse events to the FDA's MedWatch system.
• Risk Evaluation and Mitigation Strategies (REMS): For drugs with serious risks, the FDA may require specific safety measures — such as patient registries, prescriber certification, or restricted distribution — as a condition of approval.

Accelerated Pathways: Fast Track, Breakthrough, Priority Review

When a disease is serious and there are no adequate treatments, the FDA offers several mechanisms to speed development:

Pathway	Key Feature	Example
Fast Track	Rolling review of NDA sections as data become available	Many HIV/AIDS drugs in the 1990s
Breakthrough Therapy	Intensive FDA guidance throughout development	Several COVID-19 treatments
Priority Review	6-month review vs. standard 12 months	Granted when drug offers major advance
Accelerated Approval	Approval based on surrogate endpoint (e.g., tumor shrinkage) with confirmatory trial required	Many cancer drugs

These pathways do not lower the evidence bar — safety and efficacy must still be demonstrated. They simply streamline communication and review timelines.

How Long Does Approval Take?

From the first synthesis of a compound to FDA approval takes an average of 10 to 15 years and costs an estimated $1–2 billion (including the costs of failed candidates). The breakdown is roughly:

• Preclinical research: 2–5 years
• Clinical trials (Phases I–III): 6–7 years
• FDA review: 1–2 years

The COVID-19 mRNA vaccines appeared faster not because safety steps were skipped, but because unprecedented funding allowed all three phases to run simultaneously, and rolling review began before trials were complete.

Key Takeaways

• The FDA requires proof of both safety and efficacy before a new drug can be marketed.
• The process moves through preclinical research → IND → Phase I–III trials → NDA → FDA review → post-market surveillance.
• Only about 12% of drugs that enter clinical trials ultimately receive FDA approval.
• Accelerated pathways like Breakthrough Therapy designation can shorten development timelines without compromising rigor.
• Approval is not a permanent guarantee of safety — ongoing monitoring continues throughout a drug's commercial life.

This guide is for educational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making changes to your medication regimen.